A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors

Inclusion Criteria:

- The subject has a cytologically or histologically and radiologically confirmed,
advanced, recurrent, or metastatic solid tumor of the nine types listed below:

- Pancreatic Cancer

- Castration-Resistant Prostate Cancer (CRPC)

- Hepatocellular Carcinoma (HCC)

- Gastric or Gastroesophageal Junction Cancer

- Melanoma

- Small Cell Lung Cancer (SCLC)

- Ovarian cancer, primary peritoneal or fallopian tube carcinoma

- Breast cancer that is one of the following subtypes: estrogen receptor positive
breast cancer, estrogen receptor/progesterone receptor/HER2-negative
(triple-negative), or inflammatory (regardless of receptor status) disease
histology

- Non-Small Cell Lung Cancer (NSCLC)

- Certain requirements for prior therapies may apply

- The subject has documented progressive disease at screening

- Subjects having any tumor type of other than CRPC must have at least one lesion that
is not within a previously irradiated field and is measurable on CT or MRI scan

- The subject has recovered to baseline or CTCAE ≤ Grade 1 from toxicities related to
prior treatment (some exceptions apply)

- The subject is ≥ 18 years old on the day of consent

- Tissue samples from archival or fresh tissue, or a tissue block of the subject's
tumor

- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
or 1

- The subject has adequate organ function

- The subject is capable of understanding and complying with the protocol requirements
and has signed the informed consent document

- Sexually active fertile subjects (male and female), and their partners, must agree to
use medically accepted methods of contraception during the course of the study and
for 3 months after the last dose of the study drug(s)

- Female subjects of childbearing potential must have a negative pregnancy test at
screening

Exclusion Criteria:

- The subject has experienced clinically-significant hematemesis or hemoptysis of >0.5
teaspoon of red blood, or other signs indicative of pulmonary hemorrhage within 3
months before the first dose of study treatment

- The subject has a cavitating pulmonary lesion(s) or a pulmonary lesion abutting or
encasing a major blood vessel

- Certain restrictions on prior treatments apply

- The subject has received drugs used to control loss of bone mass within 4 weeks prior
to the first dose of study treatment

- The subject has known symptomatic or uncontrolled brain metastases or epidural
disease

- The subject has prothrombin time/International Normalized Ratio (PT/INR) or partial
thromboplastin time (PTT) test results that are above (1.3x)the laboratory upper
limit of normal

- The subject has a corrected QT interval(QTcF)>500 ms at screening

- The subject requires concomitant treatment, in therapeutic doses, with anticoagulants
such as warfarin or Coumadin-related agents, heparin, thrombin or FXa inhibitors, and
antiplatelet agents (low-dose aspirin (≤81 mg/day), low-dose warfarin (≤1mg/day, and
prophylactic low molecular weight heparin (LMWH) are permitted)

- The subject has uncontrolled, significant intercurrent illness

- The subject is unable to swallow capsules

- The subject is pregnant or breastfeeding

- The subject has a previously-identified allergy or hypersensitivity to components of
the study treatment formulation

- The subject is unable or unwilling to abide by the study protocol or cooperate fully
with the investigator or designee

- The subject has had another diagnosis of malignancy requiring systemic treatment
within the last two years, unless non-melanoma skin cancer, in-situ carcinoma of the
cervix, or superficial bladder cancer